Additionally, the inhibitor thiram, targeting the TRMT6/TRMT61A complex, has demonstrated efficacy in suppressing the growth of established HCC mouse xenograft models and inhibiting the formation of tumor spheroids in HCC cell lines, emphasizing the pivotal role of m1A methylation in the prognosis and therapy of HCC [73]. Here, TRMT6 is linked to hepatocellular carcinoma.